17α-ethinylestradiol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17α-ethinylestradiol
• 英文别名: (8R,9S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
• 化学式: C₂₀H₂₄O₂
• 分子量: 296.409
• InChiKey: BFPYWIDHMRZLRN-QDSUGMFFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] PI-3 KINASE INHIBITOR PRODRUGS<br/>[FR] PROMEDICAMENTS D'INHIBITEURS DE PI-3 KINASE
  申请人：SEMAFORE PHARMACEUTICALS INC

  公开号：WO2004089925A1

  公开（公告）日：2004-10-21

  The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

  这项发明提供了PI-3激酶抑制剂的新型前药。这些新型化合物是LY294002及其类似物，包括可逆性季铵化胺。
• [EN] PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS<br/>[FR] PROCÉDÉS DE PRÉPARATION DE COMPOSÉS HYDROXY-ARYLE ORTHO-ALLYLÉS
  申请人：UNIV MCMASTER

  公开号：WO2021237371A1

  公开（公告）日：2021-12-02

  The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (I).

  本申请描述了一种制备邻烯丙基羟基芳基化合物的方法，例如通过在非质子溶剂中，在氧化铝和铝烷氧化物中选择的铝化合物存在下，将烯丙醇与羟基芳基化合物反应，其中羟基芳基化合物中至少有一个碳原子位于羟基的邻位且未被取代。本申请还包括化合物的化学式（I）。
• [EN] METHODS AND COMPOSITIONS COMPRISING NOVEL CATIONIC LIPIDS<br/>[FR] PROCÉDÉS ET COMPOSITIONS COMPRENANT DE NOUVEAUX LIPIDES CATIONIQUES
  申请人：UNIV NORTH CAROLINA

  公开号：WO2009142892A1

  公开（公告）日：2009-11-26

  Provided herein are novel cationic lipids, compositions comprising the cationic lipids, and methods of using the cationic lipids. In some claims, the cationic lipids have cytotoxic activity and can be used alone or in combination with a cytotoxic bioactive compound to kill a cell. In some of these claims, the cationic lipid enhances the cytotoxic activity of the cytotoxic bioactive compound. Methods for treating a subject afflicted with a disease or unwanted condition are provided, wherein the method comprises administering a delivery system comprising a novel cationic lipid to the subject. The invention further provides methods for making delivery systems comprising the novel cationic lipids of the invention.

  本文提供了新型阳离子脂质、含有这些阳离子脂质的组合物，以及使用这些阳离子脂质的方法。在一些声明中，这些阳离子脂质具有细胞毒活性，可以单独使用或与细胞毒生物活性化合物结合使用以杀死细胞。在其中一些声明中，这些阳离子脂质增强了细胞毒生物活性化合物的细胞毒活性。提供了治疗患有疾病或不良状况的受试者的方法，其中该方法包括向受试者施用含有新型阳离子脂质的传递系统。该发明还提供了制备包含该发明的新型阳离子脂质的传递系统的方法。
• Mucosal formulation
  申请人：Boga Rameshbabu

  公开号：US20070264206A1

  公开（公告）日：2007-11-15

  A mucosal formulation for administration to mucosal membranes, such as in the mouth, nasal passage, stomach, vagina, etc., is disclosed. The mucosal formulation contains a lipid-pharmaceutical agent complex formed from phospholipids possessing a hydrophobic moiety that orients into a hydrophobic phase and a polar head moiety that orients towards the aqueous phase (i.e., “amphipathic” lipids). When placed in an aqueous medium (e.g., vaginal fluid), the phospholipids form liposomes or other small lipid vesicles (e.g., micelles) that may then be used to deliver pharmaceutical agents into a living organism.

  揭示了一种用于给粘膜膜的制剂，例如口腔、鼻腔、胃、阴道等。这种粘膜制剂包含从磷脂中形成的含有疏水部分的脂质-药物复合物，该疏水部分朝向疏水相，极性头部分朝向水相（即“两性”脂质）。当置于水性介质中（例如阴道液），磷脂形成脂质体或其他小的脂质囊泡（例如胶束），然后可用于将药物输送到活体内。
• Cytokine receptor modulators and uses thereof
  申请人：Chemtob Sylvain

  公开号：US20090048161A1

  公开（公告）日：2009-02-19

  The present invention relates to cytokine receptor-binding compounds, such as non-competitive VEGF receptor, IL-1 receptor, IL-4 receptor, or IGF-1 receptor-binding peptides and petidomimetic antagonists, and therapeutic uses of such compounds. The compounds of the present invention may be used in the treatment of cytokine-associated diseases such as proliferative disorders (for example, colon, breast, prostate, and lung cancer), abnormal neovascularization and angiogenesis, age-related macular degeneration, and proliferative and/or inflammatory skin disorders such as psoriasis.

  本发明涉及细胞因子受体结合化合物，例如非竞争性VEGF受体、IL-1受体、IL-4受体或IGF-1受体结合肽和肽类拟态拮抗剂，以及这些化合物的治疗用途。本发明的化合物可用于治疗细胞因子相关疾病，如增生性疾病（例如结肠、乳腺、前列腺和肺癌）、异常新血管生成和血管生成、年龄相关性黄斑变性以及增生性和/或炎症性皮肤疾病，如银屑病。